Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F19%3A43918247" target="_blank" >RIV/00216208:11120/19:43918247 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1093/ehjcvp/pvz016" target="_blank" >https://doi.org/10.1093/ehjcvp/pvz016</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/ehjcvp/pvz016" target="_blank" >10.1093/ehjcvp/pvz016</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Popis výsledku v původním jazyce

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1 (CHA(2)DS(2)-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA(2)DS(2)-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA(2)DS(2)-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Název v anglickém jazyce

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Popis výsledku anglicky

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1 (CHA(2)DS(2)-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA(2)DS(2)-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA(2)DS(2)-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Heart Journal: Cardiovascular Pharmacotherapy

ISSN

2055-6837

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

171-180

Kód UT WoS článku

000484382600008

EID výsledku v databázi Scopus

2-s2.0-85068427343